• Avalon GloboCare posted net loss attributable to common shareholders of USD 4.48 million, or USD 0.50 per share, for quarter ended March 31, 2026, widening 93.1% year over year.
• Operating loss widened 52.4% to USD 2.72 million, while other expense rose to USD 1.66 million.
• Net cash used in operating activities from continuing operations increased to USD 2.86 million from USD 1.69 million a year earlier.
• Cash climbed to USD 775,995 at March 31, 2026 from USD 109,091 at Dec. 31, 2025, while working capital deficit narrowed to USD 2.77 million from USD 12.65 million.
• Company continued commercialization of KetoAir breathalyzer and advanced agentic AI systems, while noting substantial doubt about its ability to continue as a going concern and plans to raise capital through equity sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalon Globocare Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-054548), on May 11, 2026, and is solely responsible for the information contained therein.